» Articles » PMID: 37731526

Procollagen Type 1 N-terminal Propeptide is Associated with Adverse Outcome in Acute Chest Pain of Suspected Coronary Origin

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Extracellular matrix (ECM) is an integral player in the pathophysiology of a variety of cardiac diseases. Cardiac ECM is composed mainly of collagen, of which type 1 is the most abundant with procollagen type 1 N-terminal Propeptide (P1NP) as a formation marker. P1NP is associated with mortality in the general population, however, its role in myocardial infarction (MI) is still uncertain, and P1NP has not been investigated in acute chest pain. The objective of the current study was to assess the role of P1NP in undifferentiated acute chest pain of suspected coronary origin.

Methods And Results: 813 patients from the Risk in Acute Coronary Syndromes study were included. This was a single-center study investigating biomarkers in consecutively enrolled patients with acute chest pain of suspected coronary origin, with a follow-up for up to 7 years. Outcome measures were a composite endpoint of all-cause death, new MI or stroke, as well as its individual components at 1, 2, and 7 years, and cardiac death at 1 and 2 years. In multivariable Cox regression analysis, quartiles of P1NP were significantly associated with the composite endpoint at 1 year of follow-up with a hazard ratio for Q4 of 1.82 (95% CI, 1.12-2.98). There was no other significant association with outcomes at any time points.

Conclusion: P1NP was found to be an independent biomarker significantly associated with adverse clinical outcome at one year in patients admitted to hospital for acute chest pain of suspected coronary origin. This is the first report in the literature on the prognostic value of P1NP in this clinical setting.

Clinicaltrialsygov Identifier: NCT00521976.

Citing Articles

The comparison of serum bone-turnover markers in different stage of chronic kidney disease and the associated impact of intradialytic cycling in patients with end-stage renal disease.

Hou Y, Chao C, Shih L, Tsai K, Lin S, Chen R Aging (Albany NY). 2025; 17(1):217-231.

PMID: 39812596 PMC: 11810069. DOI: 10.18632/aging.206177.


WISP-1 Regulates Cardiac Fibrosis by Promoting Cardiac Fibroblasts' Activation and Collagen Processing.

Li Z, Williams H, Jackson M, Johnson J, George S Cells. 2024; 13(11.

PMID: 38891121 PMC: 11172092. DOI: 10.3390/cells13110989.


Markers of Tissue Deterioration and Pain on Earth and in Space.

Patron M, Neset M, Mielkozorova M, Bisson D, Vigouroux M, Cata J J Pain Res. 2024; 17:1683-1692.

PMID: 38742243 PMC: 11089065. DOI: 10.2147/JPR.S450180.

References
1.
Zile M, OMeara E, Claggett B, Prescott M, Solomon S, Swedberg K . Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF. J Am Coll Cardiol. 2019; 73(7):795-806. DOI: 10.1016/j.jacc.2018.11.042. View

2.
Holm Nielsen S, Mouton A, DeLeon-Pennell K, Genovese F, Karsdal M, Lindsey M . Understanding cardiac extracellular matrix remodeling to develop biomarkers of myocardial infarction outcomes. Matrix Biol. 2017; 75-76:43-57. PMC: 6002886. DOI: 10.1016/j.matbio.2017.12.001. View

3.
Bornstein P . The NH(2)-terminal propeptides of fibrillar collagens: highly conserved domains with poorly understood functions. Matrix Biol. 2002; 21(3):217-26. DOI: 10.1016/s0945-053x(02)00008-2. View

4.
Oganesian A, Au S, Horst J, Holzhausen L, Macy A, Pace J . The NH2-terminal propeptide of type I procollagen acts intracellularly to modulate cell function. J Biol Chem. 2006; 281(50):38507-18. PMC: 3086210. DOI: 10.1074/jbc.M607536200. View

5.
Szulc P, Naylor K, Hoyle N, Eastell R, Leary E . Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability. Osteoporos Int. 2017; 28(9):2541-2556. DOI: 10.1007/s00198-017-4082-4. View